

Integrum chairman, Dr. Rickard Brånemark, takes on a research position at MIT

Mölnådal, 23 January 2019

Integrum, a leading provider of innovative solutions for bone anchored prosthetics, is pleased to announce that the company's founder, principal owner and chairman of the board, Dr. Rickard Brånemark, has accepted a part time research position at Massachusetts Institute of Technology (MIT) in Boston, USA.



Dr Brånemark has pioneered studies of titanium implants to anchor limb prostheses for more than 20 years. He has carried out more than 200 such operations. Dr. Brånemark is internationally recognized and has received awards including the Hanger Prize (2007) for his contribution to amputation research, the UCSF Presidential Chair Award (2016), the Blatchford Award (2017) and the Dr Per Uddén Prize (2017).

Dr. Brånemark will work closely with Professor Hugh Herr, a world leading authority in advanced amputation prosthetics and head of the MIT Media Lab Biomechatronics Group.

Professor Herr says, "Osseointegration is a potentially game changing technology in amputee care, and Dr Brånemark is bringing the most advanced osseointegration technology to our group."

As previously communicated, Integrum is already collaborating with MIT in two research projects financed by the Defense Advanced Research Project Agency (DARPA), which focus on upper limb amputated patients.

Dr. Brånemark's role at MIT provides new opportunities for Integrum to collaborate more closely with MIT within these two existing projects, and also paves the way for potential new projects.

Integrum's OPRA™ implant system is the only FDA-approved, bone anchored prosthetic solution available in the United States. OPRA™ consists of an anchorage element (fixture) and a skin penetrating device (abutment). The fixture is surgically inserted into the bone and, after a healing period, the abutment is connected to the fixture. The prosthetic limb is then attached directly to the abutment via the OPRA™ Axor™, a prosthetic connection and safety device.

For more information, please contact:

Rutger Barrdahl – CEO

Tel. +46 705 23 39 55

rutger.barrdahl@integrum.se

www.integrum.se

Certified Adviser:

Erik Penser Bank AB

Tel. +46 8 463 8000

certifiedadviser@penser.se

**About Integrum**

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden with a U.S. subsidiary in San Francisco, CA. Since 1990 osseointegration, the science behind the OPRA™ Implant System, has been helping individuals with amputations towards an improved quality of life. Thorough surgical experience gained over almost three decades from 500 surgeries in 13 countries has led to the development of Integrum's system for bone-anchored prosthetics – a beneficial alternative to the traditionally used socket prosthesis. Integrum's OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2015 for use in the U.S. under a Humanitarian Use Device (HUD) designation which was reviewed through the Humanitarian Device Exemption (HDE) pathway. The OPRA™ Implant System is the only FDA approved technology for bone anchored prosthetics available in the U.S. More information on the company and its innovative solutions for amputees can be found at www.integrum.se.